About Pulnovo

Pulnovo Medical Limited

Is a globally recognized device pioneer in the treatment for heart failure. Established in 2013 and rooted in innovation, Pulnovo Medical is committed to leveraging our deep expertise in the science of breakthrough technologie with the goal to market our innovative therapeutic solutions and benefit patients around the world.

2024

The global clinical study of PADN technology in treating Pulmonary Hypertension Associated with Left Heart Disease was successfully conducted in Portugal, Singapore, and Malaysia, with the first enrollment.

2024.06

"Chinese Expert Consensus on Percutaneous Pulmonary Artery Denervation for Pulmonary Arterial Hypertension (PADN)" was officially released.

2024.03

The world's first post-market PADN procedure was successfully performed at the Xiamen Cardiovascular Hospital Xiamen University.

2024.01

PADN obtained the U.S. Medicare coverage code by Center for Medicare&Medicaid Services(CMS) approval.

2023.12

PADN was obtained by China’s National Medical Products Administration(NMPA) approval. PADN was obtained as the FDA Humanitarian Use Device (HUD) designation.

2023.08

PADN-PH-HF clinical trial had been launched in domestic multiple clinical centers and the first patients enrollment.

2022.10

Pulnovo Medical completed a multi-million dollar equity financing round through Yuanbio Venture Capital, OrbiMed Healthcare Fund Management, Cenova Capital, Lilly Asia Ventures(LAV), GaoRong Capital，HuiHe Capital and GC&H Investments.